Technical Analysis for AADI - Aadi Biosciences, Inc.

Grade Last Price % Change Price Change
F 12.87 -0.92% -0.12
AADI closed down 0.92 percent on Thursday, January 26, 2023, on 67 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Flat

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Gapped Up Strength 0.00%
50 DMA Support Bullish -0.92%
Outside Day Range Expansion -0.92%
Up 3 Days in a Row Strength -0.92%
Up 4 Days in a Row Strength -0.92%
Crossed Above 50 DMA Bullish -0.85%
MACD Bullish Centerline Cross Bullish -0.85%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 21 hours ago
50 DMA Support about 21 hours ago
Down 1% about 21 hours ago
Fell Below 50 DMA about 22 hours ago
Fell Below 10 DMA about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARRO (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Disease Oncology Tumor Antineoplastic Drugs Drug Delivery Signal Transduction mTOR Mtor Inhibitors

Is AADI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.15
52 Week Low 11.0
Average Volume 79,359
200-Day Moving Average 13.47
50-Day Moving Average 12.89
20-Day Moving Average 12.64
10-Day Moving Average 12.87
Average True Range 0.45
RSI 52.38
ADX 10.0
+DI 21.38
-DI 17.99
Chandelier Exit (Long, 3 ATRs) 11.89
Chandelier Exit (Short, 3 ATRs) 13.14
Upper Bollinger Bands 13.23
Lower Bollinger Band 12.05
Percent B (%b) 0.69
BandWidth 9.37
MACD Line 0.04
MACD Signal Line -0.02
MACD Histogram 0.0583
Fundamentals Value
Market Cap 606.33 Million
Num Shares 47.1 Million
EPS -0.28
Price-to-Earnings (P/E) Ratio -46.80
Price-to-Sales 4.81
Price-to-Book 1.74
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.46
Resistance 3 (R3) 13.51 13.36 13.36
Resistance 2 (R2) 13.36 13.21 13.33 13.33
Resistance 1 (R1) 13.11 13.11 13.04 13.07 13.30
Pivot Point 12.96 12.96 12.92 12.94 12.96
Support 1 (S1) 12.72 12.81 12.64 12.67 12.44
Support 2 (S2) 12.57 12.72 12.54 12.41
Support 3 (S3) 12.32 12.57 12.38
Support 4 (S4) 12.28